Skip to content

This Site is Intended for Healthcare Professionals Only

Search AI Powered

Latest Stories

BREAKING: Pharma firms fined over £3m after competition probe

Four pharmaceutical companies who broke competition law in relation to the supply of an antidepressant have been fined more than £3.4 million.

Two of the four firms have been asked to make a payment of £1 million directly to the NHS.


This follows a recent probe by the Competition and Markets Authority (CMA) into the supply of nortriptyline, which has also led to the disqualification of a company director.

Fined for market sharing

The CMA found that King Pharmaceuticals Ltd and Auden Mckenzie (Pharma Division) Ltd shared between them the supply of nortriptyline – a drug relied upon by thousands of NHS patients every day to relieve symptoms of depression – to a large pharmaceutical wholesaler.

Rather than competing, the two companies agreed that King would supply only 25mg and Auden Mckenzie only 10mg tablets, between September 2014 and May 2015.

The CMA said the two firms – which have now admitted to breaking the law – “also colluded to fix quantities and prices.”

“After this market sharing ended, Accord-UK Ltd took control of Auden Mckenzie’s nortriptyline business, and so the CMA holds the company responsible for Auden’s illegal conduct,” the investigators said.

As a result, the CMA has fined King and Accord-UK £75,573 and £1,882,238 respectively.

Accord and Auden Mckenzie have also agreed to make a £1 million payment to the NHS in connection with the case.

Fined for information exchange

The competition watchdog said it has also fined King, Lexon (UK) Ltd and Alissa Healthcare Research Ltd for illegally sharing commercially sensitive information, to try to keep nortriptyline prices up.

The three suppliers exchanged information about prices, the volumes they were supplying, and Alissa’s plans to enter the market between 2015 and 2017. Significantly, this was when the cost of the drug was falling, according to the CMA.

King and Alissa, who have both admitted to "breaking the law," have been fined £75,573 and £174,912 respectively, while Lexon, who have contested their involvement in the infringement, have been fined a total of £1,220,383.

Disqualification

Meanwhile, exercising its power under the Company Directors Disqualification Act, the CMA has secured the disqualification of Dr Philip Hallwood, a director at King Pharmaceuticals; he cannot be involved in the management of any UK company for seven years.

Community pharmacists can "lose out"

Commenting on the news, Chief Executive of the National Pharmacy Association Mark Lyonette said: “As restricted competition can lead to the NHS and taxpayers facing higher costs, we are not surprised that the CMA has imposed significant financial penalties on these companies. Community pharmacists can also lose out if a lack of choice results in higher medicines prices.”

More For You

Community Pharmacy England (CPE) chief executive Janet Morrison was one of the signatories of the statement

Community Pharmacy England (CPE) chief executive Janet Morrison was one of the signatories of the statement

Primary care leaders join forces in effort to 'transform investment into primary care'

Community Pharmacy England (CPE) has teamed up with other national primary care bodies to urge the government to allocate more funds towards the sector.

In a joint statement released on the back of the government’s spending review, last week, the organisations welcomed the government’s continued determination to ‘shift care from hospitals to community and from sickness to prevention’ but warned that this would not be possible ‘without further investment in primary care’.

Keep ReadingShow less
Cancer patients warned against using weight-loss jabs

Macmillan Cancer Support said there is not enough evidence on how the weight-loss jabs might affect anti-cancer treatments.

iStock

Cancer patients warned against using weight-loss jabs

Cancer patients have been advised to consult their doctor before taking any weight-loss jabs.

Macmillan Cancer Support has issued this advisory following a surge in calls by cancer patients asking whether they can take fat loss jabs such as Wegovy and Mounjaro.

Keep ReadingShow less
Kamson Pharmacy to deliver more clinical services after installing hub and spoke technology

The FLOWRx auto hub in the new Kamson warehouse in Uckfield.

Kamson Pharmacy to deliver more clinical services after installing hub and spoke technology


Kamsons Pharmacy has announced that it has implemented a state-of-the-art hub and spoke dispensing model with the aim of freeing up more time to deliver clinical services.

Keep ReadingShow less
RPS group aims to tackle barriers holding back black pharmacy students

Work is underway to improve inclusivity in teaching

Pic credit: iStock

RPS group aims to tackle barriers holding back black pharmacy students

A cross-sector group aimed at tackling barriers that block the progression of black students and trainee pharmacists held its first meeting this week.

The Royal Pharmaceutical Society (RPS) has created the Differential Attainment Oversight Group to address issues that black or black British African student pharmacists and foundation trainees face such as limited access to work experience, financial support and visible role models in education and training.

Keep ReadingShow less
Older adult organizing medicine bottles in a cool, dry storage area during warm weather.

People are being advised to keep medicine below 25° C

Pic credit: iStock

Pharmacies advise patients on storing medicines safely during heatwave

Patients are being given important advice and guidance on the impact heat can have on their medicine and where to keep different medicines as the UK goes through a heatwave.

People are being advised to keep medicine below 25° C if they are able to, unless storage instructions state it needs to be kept at an alternative temperature, such as drugs that need to be refrigerated.

Keep ReadingShow less